EZZ Life Science Holdings (ASX:EZZ) Cash-to-Debt : 153.41 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is EZZ Life Science Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. EZZ Life Science Holdings's cash to debt ratio for the quarter that ended in Jun. 2024 was 153.41.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, EZZ Life Science Holdings could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for EZZ Life Science Holdings's Cash-to-Debt or its related term are showing as below:

ASX:EZZ' s Cash-to-Debt Range Over the Past 10 Years
Min: 28.88 Med: 112.08 Max: 262.72
Current: 153.41

During the past 5 years, EZZ Life Science Holdings's highest Cash to Debt Ratio was 262.72. The lowest was 28.88. And the median was 112.08.

ASX:EZZ's Cash-to-Debt is ranked better than
81.1% of 1487 companies
in the Biotechnology industry
Industry Median: 6.38 vs ASX:EZZ: 153.41

EZZ Life Science Holdings Cash-to-Debt Historical Data

The historical data trend for EZZ Life Science Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

EZZ Life Science Holdings Cash-to-Debt Chart

EZZ Life Science Holdings Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Cash-to-Debt

262.72

112.08

99.67

28.88

153.41

EZZ Life Science Holdings Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial			99.67	180.87	28.88	41.51	153.41

Competitive Comparison of EZZ Life Science Holdings's Cash-to-Debt

For the Biotechnology subindustry, EZZ Life Science Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EZZ Life Science Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where EZZ Life Science Holdings's Cash-to-Debt falls into.

EZZ Life Science Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

EZZ Life Science Holdings's Cash to Debt Ratio for the fiscal year that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	19.023	/	(0.124	+	0)
	=	153.41

EZZ Life Science Holdings's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	19.023	/	(0.124	+	0)
	=	153.41

EZZ Life Science Holdings (ASX:EZZ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

EZZ Life Science Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of EZZ Life Science Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

EZZ Life Science Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EZZ Life Science Holdings Ltd (ASX:EZZ) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

55-59 Parramatta Road, Shop 1, Lidcombe, NSW, AUS, 2141

Website

https://www.ezzlife.com.au

EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.

EZZ Life Science Holdings Headlines

No Headlines